JP Morgan Downgrades Enfusion to Underweight, Lowers Price Target to $9

Enfusion, Inc. +0.97%

Enfusion, Inc.

ENFN

9.39

+0.97%

JP Morgan analyst Alexei Gogolev downgrades Enfusion (NYSE: ENFN) from Neutral to Underweight and lowers the price target from $11 to $9.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via